People: ContraFect Corp (CFRX.OQ)
21 Nov 2019
Dr. Cara Cassino M.D., is General Counsel, Secretary, Chief Medical Officer of the Company., effective 25 September 2015. She has extensive experience in the design and execution of drug development programs across a broad range of therapeutic areas, and has led more than 20 regulatory submissions that resulted in approvals in the United States and abroad. Dr. Cassino was previously Senior Vice President, Global Clinical Development at Forest Laboratories, Inc. (“Forest”) where she served as a member of Forest’s R&D Executive Leadership team and was responsible for the clinical development of a portfolio of over 35 compounds, (including 7 drugs in the anti-infective space) and was also instrumental in the clinical due diligence process for Forest’s $2.9 billion acquisition of Aptalis Pharma and $1.1 billion acquisition of Furiex Pharmaceuticals. Prior to joining Forest, Dr. Cassino held a number of senior executive positions at Pfizer Inc. (“Pfizer”), including Global Medical Team Leader of Pfizer’s antibacterial franchise and also Medicines Development Group Vice President for Pulmonary Vascular Disease and Rare Disease. Prior to joining Pfizer, Dr. Cassino held positions of increasing responsibility at Boehringer Ingelheim GmbH (“Boehringer”), culminating in the role of Executive Medical Director of Boehringer’s late stage respiratory franchise in the U.S. Prior to joining Boehringer, Dr. Cassino was a member of the academic faculty of the Division of Pulmonary and Critical Care Medicine at the New York University (“NYU”) School of Medicine. Dr. Cassino received both her medical degree, and B.A. in Chemistry and Fine Arts, summa cum laude and Phi Beta Kappa, from NYU. Dr. Cassino completed her internship and residency in Internal Medicine at NYU/Bellevue Hospital, followed by fellowship in Pulmonary/Critical Care Medicine at NYU and Mount Sinai Medical Center in New York City.
|Total Annual Compensation,||--|
|Restricted Stock Award,||--|
|Long-Term Incentive Plans,||--|
|Fiscal Year Total,||--|